These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3319474)

  • 41. Availability of riboflavin from food sources as judged by urinary excretion of the vitamin.
    EVERSON GJ; WHEELER EK; WALKER HJ
    Fed Proc; 1947; 6(1):407. PubMed ID: 20343861
    [No Abstract]   [Full Text] [Related]  

  • 42. Availability of riboflavin of ice cream, peas, and almonds judged by urinary excretion of the vitamin by women subjects.
    EVERSON G; WHEELER E
    J Nutr; 1948 Feb; 35(2):209-23. PubMed ID: 18900263
    [No Abstract]   [Full Text] [Related]  

  • 43. Variation in riboflavin excretion.
    GERSHOFF SN; HEGSTED DM; JOLLY DH; TRULSON MF
    J Nutr; 1956 Dec; 60(4):581-97. PubMed ID: 13385722
    [No Abstract]   [Full Text] [Related]  

  • 44. A clinical method for determination of riboflavin standard in urine after a test dose and the riboflavin excretion of clinically normal subjects.
    DESSNER L
    Acta Odontol Scand; 1952 Jun; 10(1):1-13. PubMed ID: 14952268
    [No Abstract]   [Full Text] [Related]  

  • 45. [Excretion of riboflavin in the urine in experimental tumors].
    CHERKES LA; APTEKAR' SG
    Arkh Patol; 1960; 22(2)():27-38. PubMed ID: 13809652
    [No Abstract]   [Full Text] [Related]  

  • 46. [Riboflavinuria after parenteral loading in hyperthyroid patients in relation to the surgical operation].
    PALAGIANO V
    Acta Chir Ital; 1962; 18():183-92. PubMed ID: 14483294
    [No Abstract]   [Full Text] [Related]  

  • 47. Riboflavin as an oral tracer for monitoring compliance in clinical research.
    Ramanujam VM; Anderson KE; Grady JJ; Nayeem F; Lu LJ
    Open Biomark J; 2011; 2011(4):1-7. PubMed ID: 21949554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The urinary excretion of metabolites of riboflavine by man.
    West DW; Owen EC
    Br J Nutr; 1969 Nov; 23(4):889-98. PubMed ID: 5357053
    [No Abstract]   [Full Text] [Related]  

  • 49. [Urinary riboflavin in animals with implanted tumors].
    KAGAN IaA
    Vopr Onkol; 1955; 1(3):88-91. PubMed ID: 13299800
    [No Abstract]   [Full Text] [Related]  

  • 50. Further studies on the relation between in vitro disintegration time of tablets and the urinary excretion rates of riboflavin.
    MORRISON AB; CHAPMAN DG; CAMPBELL JA
    J Am Pharm Assoc Am Pharm Assoc; 1959 Nov; 48():634-7. PubMed ID: 13854016
    [No Abstract]   [Full Text] [Related]  

  • 51. Biliary excretion of riboflavin in man.
    Levy G; Mosovich LL; Allen JE; Yaffe SJ
    J Pharm Sci; 1972 Jan; 61(1):143-4. PubMed ID: 5058638
    [No Abstract]   [Full Text] [Related]  

  • 52. Factors affecting the absorption of riboflavin in man.
    Levy G; Jusko WJ
    J Pharm Sci; 1966 Mar; 55(3):285-9. PubMed ID: 5960174
    [No Abstract]   [Full Text] [Related]  

  • 53. The urinary excretion of riboflavin by college women.
    BREWER W; PORTER T
    J Nutr; 1946 Dec; 32(6):583-96. PubMed ID: 20277355
    [No Abstract]   [Full Text] [Related]  

  • 54. RIBOFLAVIN intake versus excretion.
    Nutr Rev; 1951 Feb; 9(2):49-51. PubMed ID: 14807296
    [No Abstract]   [Full Text] [Related]  

  • 55. SOLUBILITY and biologic acitivity of riboflavin derivatives.
    Nutr Rev; 1946 Mar; 4():93. PubMed ID: 21021038
    [No Abstract]   [Full Text] [Related]  

  • 56. [On the excretion of riboflavin in children from 3 to 7 years of age].
    MASLENIKOVA EM; KOSENKO SA
    Vopr Pitan; 1962; 21():31-6. PubMed ID: 13933342
    [No Abstract]   [Full Text] [Related]  

  • 57. A STUDY OF URINARY RIBOFLAVIN EXCRETION IN MAN.
    Axelrod AE; Spies TD; Elvehjem CA; Axelrod V
    J Clin Invest; 1941 Mar; 20(2):229-32. PubMed ID: 16694828
    [No Abstract]   [Full Text] [Related]  

  • 58. Water-soluble methylol derivatives of riboflavin.
    SCHOEN K; GORDON SM
    Arch Biochem; 1949 May; 22(1):149-59. PubMed ID: 18127593
    [No Abstract]   [Full Text] [Related]  

  • 59. Multiple dose excretion kinetics.
    WIEGAND RG; BUDDENHAGEN JD; ENDICOTT CJ
    J Pharm Sci; 1963 Mar; 52():268-73. PubMed ID: 14000530
    [No Abstract]   [Full Text] [Related]  

  • 60. Enzymatic Studies on the Mechanism of the Resistance of Pneumococcus to Drugs: II. The Inhibition of Dehydrogenase Activities by Drugs; Antagonistic Effects of Riboflavin to Inhibitions.
    Sevag MG; Gots JS
    J Bacteriol; 1948 Dec; 56(6):723-35. PubMed ID: 16561625
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.